Kimberly Hollandsworth, MD
Dermatopathology · Cleveland, OHNPI 1255316105
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Galderma Laboratories, L.p. accounts for 61.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $602 and has fallen 77.3% since, to $137 in 2025.
Across 54 payments — averaging $38.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$1K
- AbbVie$230
- E.r. Squibb & Sons, L.L.C.$171
- Amgen$125
- UCB, Inc.$123
- Sun Pharmaceutical Industries Inc.$107
- plus $42 from 2 others
What the payments were for
- Food & beverage$2,080100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 34 | $1,282 |
| AbbVie | 2 | $230 |
| E.r. Squibb & Sons, L.L.C. | 13 | $171 |
| Amgen | 1 | $125 |
| UCB, Inc. | 1 | $123 |
| Sun Pharmaceutical Industries Inc. | 1 | $107 |
| GSK | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,080 in reported general payments places this provider in the 60th percentile of 25 dermatopathology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 19 | $388,793 |
| Dupixent PenDupilumab | 16 | $59,889 |
| Dupixent SyringeDupilumab | 12 | $44,370 |
| Clobetasol Propionate | 59 | $4,093 |
| Fluocinonide | 65 | $3,276 |
| Metronidazole | 43 | $2,862 |
| Fluorouracil | 37 | $2,689 |
| Doxycycline Monohydrate | 74 | $2,151 |
| Ketoconazole | 134 | $1,473 |
| Tretinoin | 14 | $1,470 |
| Calcipotriene | 13 | $1,210 |
| CiclopiroxCiclopirox Olamine | 42 | $914 |
| Triamcinolone Acetonide | 71 | $791 |
| Dutasteride | 22 | $615 |
| ValacyclovirValacyclovir Hcl | 29 | $550 |
Paid to pharmacies, not to this prescriber.
Other dermatopathology in Cleveland
- Melissa PiliangCleveland$123K
- Stephen SomachCleveland$3K
- Timothy ChangCleveland$800
- Jonathan BassCleveland$20
- Neera Agarwal AntalHudson$39K
- Adam HesselDublin$11K
- Katherine FeningMayfield Heights$10K
- Lindsey DohseChillicothe$7K
- Omar SalemSylvania$5K
- Joshua WeaverAkron$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.